Compass Therapeutics Launches Underwritten Public Offering

Strategic Insights -

Compass Therapeutics, a clinical-stage, oncology-focused biopharmaceutical company, has announced the launch of an underwritten public offering of its common stock and pre-funded warrants to purchase shares of its common stock. The offering is contingent on market conditions and the company plans to use the net proceeds to conduct initial preparations for commercial readiness, fund research and clinical development of its product candidates, and for general corporate purposes.

Key Takeaways:

  • Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases.
  • The company has a robust pipeline of novel product candidates designed to target multiple critical biological pathways required for an effective anti-tumor response.
  • Compass plans to advance its product candidates through clinical development as both standalone therapies and in combination with proprietary pipeline antibodies based on supportive clinical and nonclinical data.
  • The company has appointed Jefferies, Piper Sandler, and Guggenheim Securities as joint active bookrunning managers for the offering.
  • Compass has a shelf registration statement on Form S-3 relating to the securities offered in the public offering, filed with the Securities and Exchange Commission on August 30, 2024, and declared effective on September 6, 2024.
  • The company plans to use the net proceeds from the offering for initial preparations for commercial readiness, research and clinical development of its product candidates, and general corporate purposes.
  • Various statements in the release concerning the timing, size, structure, and completion of the proposed public offering may constitute forward-looking statements, which are based on management's current expectations of future events.

Statistics:

  • Compass Therapeutics was founded in 2014 and is headquartered in Boston, Massachusetts.
  • The company has a robust pipeline of 5 novel product candidates in clinical development.
  • Compass plans to advance its product candidates through clinical development as both standalone therapies and in combination with proprietary pipeline antibodies.
  • The shelf registration statement on Form S-3 relates to the securities offered in the public offering and was filed with the Securities and Exchange Commission on August 30, 2024.
  • The registration statement declared effective by the SEC on September 6, 2024.
  • The company plans to use the net proceeds from the offering for initial preparations for commercial readiness, research and clinical development of its product candidates, and general corporate purposes, totaling $100 million.

Sources:

  • Globe Newswire press release, "Compass Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants", August 12, 2025.
  • Compass Therapeutics Investor Presentation, June 2025.
  • Compass Therapeutics Form 10-K for the year ended December 31, 2024, filed on February 27, 2025.